Pharmaceuticals, Biotechnology and Life Sciences
If approved, Kalydeco (ivacaftor) will be the first and only medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, as young as 6 months of age.
Novocure has posted quarterly net revenues of $101.8 million, representing 39 percent growth versus the first quarter 2019 and 3 percent growth versus the fourth quarter 2019.
Nicoya, a leading provider of advanced analytical instruments for the biotechnology and pharmaceutical industries, announced today that they will be offering Surface Plasmon Resonance (SPR) technical support to all researchers – at no cost – during COVID-19.
JCRI said Wednesday it is seeking approval from the Food and Drug Administration (FDA) under its Emergency Use Authorization (EUA) for using the Canady Helios Cold Plasma HERO (Humidified Electrical Reactive Oxygen) System for the treatment of patients infected with COVID-19 virus.
Genespire has secured an injection of $16M in A financing round, and also has named a new CEO, with new board members joining in.
FDA has approves Merck’s Keytruda, pembrolizumab, for use at an additional recommended dose of 400 mg every six weeks for all approved adult indications.
Mylan and Biocon have launched Fulphila, a biosimilar to Neulasta (pegfilgrastim), as it was approved by Health Canada to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.
LabCorps’s Q1 revenue of $2.82 billion is up 1% over $2.79 billion last year, while the same period diluted EPS of ($3.27), which include goodwill and other asset impairments of $4.43 per share.
Venatorx Pharmaceuticals has teamed up with GARDP to develop antibiotics for hospital-acquired infections, which comes at a critical time with a study showing bacterial infections present in half of the deceased COVID-19 patients.
First-Quarter 2020 Revenues of $12.0 Billion, Reflecting 7% Operational Decline; Excluding the Impact from Consumer Healthcare(1), Revenues Declined 1% Operationally.